Business
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated mid-year 2026The Company raised net proceeds of approximately $8.0 million in Q1 2026 and an additional $5.0 million in Q2 2026 to date, for aggregate net proceeds of approximately $13.0 million, through its established at-the-market programProjected cash runway beyond the expected AMPLIFY-7P Phase
About this update from Elicio Therapeutics, Inc.
[{"type":"image","alt":"Elicio Therapeutics Inc.","displaySize":"","headline":null,"caption":"Elicio Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qeuRU9Dt4U9Q8E7L.P_kqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995","width":300,"height":108},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/qeuRU9Dt4U9Q8E7L.P_kqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated mid-year 2026","length":214,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company raised net proceeds of approximately $8.0 million in Q1 2026 and an additional $5.0 million in Q2 2026 to date, for aggregate net proceeds of approximately $13.0 million, through its established at-the-market program","length":228,"tagName":"p"}]},{"val":[{"type":"text","content":"Projected cash runway beyond the expected AMPLIFY-7P Phase 2 final DFS data","length":75,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":517,"olType":false},{"type":"text","content":"BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the quarter ended March 31, 2026, and provided recent corporate and clinical updates. “We remain focused on advancing the Phase 2 AMPLIFY-7P trial and anticipate reaching the event-driven primary DFS analysis of ELI-002 7P in post-resection KRAS-driven PDAC mid-year 2026,” said Robert Connelly, Chief Executive Officer of Elicio. “We are encouraged by the durability of T-cell responses and clinical observations to date, supporting the potential of ELI-002 7P to favorably impact outcomes as monotherapy in the adjuvant PDAC setting. Wi...